These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29035705)

  • 1. Linking patients with buprenorphine treatment in primary care: Predictors of engagement.
    Simon CB; Tsui JI; Merrill JO; Adwell A; Tamru E; Klein JW
    Drug Alcohol Depend; 2017 Dec; 181():58-62. PubMed ID: 29035705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of early dropout in outpatient buprenorphine/naloxone treatment.
    Marcovitz DE; McHugh RK; Volpe J; Votaw V; Connery HS
    Am J Addict; 2016 Sep; 25(6):472-7. PubMed ID: 27442456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
    Carter J; Zevin B; Lum PJ
    Addict Sci Clin Pract; 2019 May; 14(1):20. PubMed ID: 31060600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.
    Bhatraju EP; Grossman E; Tofighi B; McNeely J; DiRocco D; Flannery M; Garment A; Goldfeld K; Gourevitch MN; Lee JD
    Addict Sci Clin Pract; 2017 Feb; 12(1):7. PubMed ID: 28245872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.
    Weinstein ZM; Gryczynski G; Cheng DM; Quinn E; Hui D; Kim HW; Labelle C; Samet JH
    Drug Alcohol Depend; 2018 Aug; 189():166-171. PubMed ID: 29958128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
    Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
    J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
    Turner BJ; Laine C; Lin YT; Lynch K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalized opioid-dependent patients: Exploring predictors of buprenorphine treatment entry and retention after discharge.
    Lee CS; Liebschutz JM; Anderson BJ; Stein MD
    Am J Addict; 2017 Oct; 26(7):667-672. PubMed ID: 28324627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients.
    Lee CS; Rosales R; Stein MD; Nicholls M; O'Connor BM; Loukas Ryan V; Davis EA
    Am J Addict; 2019 Sep; 28(5):409-412. PubMed ID: 31251426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
    Dayal P; Balhara YPS
    J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
    Bell J; Trinh L; Butler B; Randall D; Rubin G
    Addiction; 2009 Jul; 104(7):1193-200. PubMed ID: 19563562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
    Fingerhood MI; King VL; Brooner RK; Rastegar DA
    Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of substance use disorder treatment seeking visits after emergency department-initiated buprenorphine.
    Jennings LK; Bogan C; McCauley JJ; Moreland A; Lane S; Ward R; Hartwell KJ; Haynes L; Brady KT
    Am J Emerg Med; 2020 May; 38(5):975-978. PubMed ID: 32081555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program.
    Payne BE; Klein JW; Simon CB; James JR; Jackson SL; Merrill JO; Zhuang R; Tsui JI
    Drug Alcohol Depend; 2019 Jul; 200():71-77. PubMed ID: 31103879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine treatment in an urban community health center: what to expect.
    Cunningham C; Giovanniello A; Sacajiu G; Whitley S; Mund P; Beil R; Sohler N
    Fam Med; 2008; 40(7):500-6. PubMed ID: 18928077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication Treatment With Methadone or Buprenorphine: Differential Reasons for Premature Discharge.
    Proctor SL; Birch A; Herschman PL
    J Addict Med; 2019; 13(2):113-118. PubMed ID: 30199427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.